Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases
暂无分享,去创建一个
Ashwani K. Singal | J. Bloomer | A. Singal | M. Shoreibah | Evan J. Raff | Donny Kakati | Joseph R. Bloomer | Mohamed Shoreibah | Khalid Rasheed | K. Rasheed | E. Raff | Donny D Kakati | Mohamed Shoreibah
[1] R. Wiesner,et al. Evolving Frequency and Outcomes of Liver Transplantation Based on Etiology of Liver Disease , 2013, Transplantation.
[2] D. García-Compeán,et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. , 2011, Annals of hepatology.
[3] P. O S I T I O N S T A T E M E N T,et al. Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.
[4] P. Rosenthal,et al. American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.
[5] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[6] F. Marra,et al. Adipokines in liver diseases , 2009, Hepatology.
[7] Chien-Jen Chen,et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. , 2008, Gastroenterology.
[8] M. Lai,et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection , 2006, Hepatology.
[9] C. Tilquin,et al. Risk Adjustment in Outcome Assessment: the Charlson Comorbidity Index , 1993, Methods of Information in Medicine.
[10] I. Wanless,et al. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.
[11] J. Heimbach,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.
[12] A. Alberti,et al. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin. , 2008, World journal of gastroenterology.
[13] C. Palmeira,et al. Hyperglycemia decreases mitochondrial function: the regulatory role of mitochondrial biogenesis. , 2007, Toxicology and applied pharmacology.
[14] A. Jenkins,et al. Associations between liver histology and severity of the metabolic syndrome in subjects with nonalcoholic fatty liver disease. , 2005, Diabetes care.
[15] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[16] Z. Younossi,et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[17] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[18] Manal M. Hassan,et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma , 2010, Cancer.
[19] Michael Roden,et al. Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance , 2006, Nature Clinical Practice Endocrinology &Metabolism.
[20] F. Folli,et al. Insulin and insulin‐like growth factor‐1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways , 1999, Hepatology.
[21] T. Mizoue,et al. Prospective study of diabetes mellitus and liver cancer in Japan , 2001, Diabetes/metabolism research and reviews.
[22] J. Crespo,et al. Gene expression of tumor necrosis factor α and TNF‐receptors, p55 and p75, in nonalcoholic steatohepatitis patients , 2001 .
[23] A. Facciorusso. The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. , 2013, Current diabetes reviews.
[24] V. de Lédinghen,et al. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. , 2006, Journal of hepatology.
[25] W. Aronow. Updated National Cholesterol Education Program III guidelines. , 2005, Journal of the American Medical Directors Association.
[26] P. Hayes,et al. Prevalence of and Risk Factors for Hepatic Steatosis and Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: the Edinburgh Type 2 Diabetes Study , 2011, Diabetes Care.
[27] Aijaz Ahmed,et al. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.
[28] K. Cusi,et al. Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[29] H. Adami,et al. Excess risk of primary liver cancer in patients with diabetes mellitus. , 1996, Journal of the National Cancer Institute.
[30] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[31] P. Bedossa,et al. Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.
[32] J. Shaw,et al. Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.
[33] C. Miranda,et al. Alcohol and HCV Chronic Infection Are Risk Cofactors of Type 2 Diabetes Mellitus for Hepatocellular Carcinoma in Italy , 2010, International journal of environmental research and public health.
[34] T. Saibara,et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients , 2014, Journal of Gastroenterology.
[35] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[36] M Linet,et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. , 1997, Journal of the National Cancer Institute.
[37] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[38] Michael Charlton,et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. , 2012, Gastroenterology.
[39] H. Tilg,et al. Adiponectin and its receptors in patients with chronic hepatitis C. , 2005, Journal of hepatology.
[40] J. Bruix,et al. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma , 2010, European journal of gastroenterology & hepatology.
[41] S. Sanderson,et al. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.
[42] F. Davis,et al. Re: Excess risk of primary liver cancer in patients with diabetes mellitus. , 1997, Journal of the National Cancer Institute.
[43] A. Hashmi,et al. Diabetes mellitus and decompensated cirrhosis: Risk of hepatic encephalopathy in different age groups (糖尿病与失代偿性肝硬化:不同年龄组的肝性脑病风险) , 2013, Journal of diabetes.
[44] R O Morgan,et al. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study , 2005, Gut.
[45] N. Chalasani,et al. Erratum: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology (Gastroenterology (2012) 142 (1592-1609)) , 2012 .
[46] Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. , 1994, Hepatology.
[47] Henry Völzke,et al. Multicausality in fatty liver disease: is there a rationale to distinguish between alcoholic and non-alcoholic origin? , 2012, World journal of gastroenterology.
[48] Lu-Yu Hwang,et al. Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus , 2002, Hepatology.
[49] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[50] A. Iwama,et al. Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells , 2013, PloS one.
[51] Sara Rosenbaum,et al. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. , 2005, The American journal of cardiology.
[52] P. Zimmet,et al. Diagnosis and classification of diabetes mellitus , 2002 .
[53] A. Singal,et al. Recent trends in the epidemiology of alcoholic liver disease , 2013, Clinical liver disease.
[54] Rohit Loomba,et al. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. , 2013, Journal of diabetes and its complications.